Canada's Accucaps enters EU gelatin market
encapsulation products across the high-potential EU after being
added to the bloc's consolidated list of approved suppliers.
Accucaps was founded in 1989 and is currently engaged in global expansion. The EU is identified as the most important region for this programme.
Denis Decarie, Accucaps' global business development manager, told NutraIngredients.com that entering this market will "alleviate the relative importance of the North American market on Accucaps."
The company already supplies product to the UK, Belgium and Denmark. In other countries it plans to establish relationships with local representatives and supply directly from Canada. It may, however, keep some product to hand in Europe so as to avoid delays caused by transportation and to serve its customers more efficiently.
"We've worked hard to earn our reputation as a reliable company that delivers quality manufacturing," said Peter Wares, director of Accucaps' health care business unit.
"This certification confirms that Accucaps is positioned to service the international marketplace and we look forward to the growth opportunities this approval from the EU affords us."
Accucaps is currently a $100m company, with the majority of its sales coming from the $18bn US OTC market. In the next five years it aims to achieve sales of $15m.
